Investors should monitor upcoming IND filings for SC451 and first-in-human data from SG293 trials as key catalysts; the extended cash runway into late 2026 reduces near-term dilution risk despite no revenue
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 4 $3.82entry
- T+1 · 9mo ago −10.73%α −10.16% · $3.41
- T+5 · 8mo ago −17.54%α −16.21% · $3.15
- T+20 · 8mo ago −20.16%α −15.74% · $3.05
- T+60 · 6mo ago −18.06%α −28.15% · $3.13
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sana Biotechnology reported Q4 and full-year 2025 financial results alongside significant clinical and operational progress, including 12-month data from its UP421 type 1 diabetes study showing survival and function of hypoimmune-modified islet cells without immunosuppression, publication in NEJM, advancement of SC451 and SG293 programs toward clinical trials, and a strengthened cash position of $138.4 million providing runway into late 2026 following $133.7 million in equity raises.
Key Financial Metrics
Key Facts
- 12-month clinical data from UP421 study show hypoimmune-modified islet cells survive, function, and evade immune detection without immunosuppression in a type 1 diabetes patient
- NEJM published 12-week results and an accompanying editorial, validating scientific significance
- SC451 (iPSC-derived hypoimmune islet therapy) on track for IND filing and Phase 1 start as early as 2026
- SG293 (in vivo CAR-T fusosome) expected to generate first-in-human data in blood cancers in 2026
- Raised $133.7 million via ATM and public offering in 2025; cash position at $138.4 million as of Dec 31, 2025
- Non-GAAP net loss improved to $170.1 million in 2025 from $263.1 million in 2024 due to R&D prioritization and cost reductions
- Appointed new CFO, Brian Piper, in Q1 2026
Financial Impact
Reduced cash burn from $195.1M in 2024 to $138.5M in 2025 (Non-GAAP); $133.7M raised in equity financing offsets operating losses
Risk Factors
- Clinical development risks in early-stage programs (SC451, SG293)
- Heavy reliance on successful translation of preclinical/early clinical data into later-stage efficacy
- Future financing needs beyond late 2026 could lead to dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248908 |
Track record
12 reports on SANA
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +13.50% at T+20 after the May 11, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.37 Now $1.88 −20.68% settles Dec 7
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $2.34 Now $1.88 −19.66% settles Dec 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Entry $3.79 to $3.17 Now $1.88 −50.40% ▼ −16.36% −15.30% vs SPY
- May 11, 202627w ago 8-K Neutral 4/10 No price data
- May 11, 202627w ago Press Release Bearish 6/10 Entry $3.26 to $2.82 Now $1.88 +42.33% ▲ +13.50% +11.77% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 4/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
- Apr 24, 202629w ago 8-K Neutral 2/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
- Apr 13, 202631w ago 8-K Bullish 6/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
- Apr 13, 202631w ago Press Release Bullish 7/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers